ANVISA Medical Device Regulation 2026: Brazil and Chile's Technical Exchange and Its Impact

ANVISA Medical Device Regulation 2026: Brazil and Chile's Technical Exchange and Its Impact

Brazil's ANVISA and Chile's ISP held a technical exchange from July 6-10, 2026, to deepen regulatory cooperation. This episode explores the key topics discussed—including Brazilian GMP certification, import controls, and post-market surveillance—and analyzes the implications for medical device manufacturers. We discuss how this collaboration supports the broader trend of regulatory convergence in Latin America and what practical steps companies can take to prepare for a more harmonized market. Key Questions: - What was the purpose of the technical exchange between Brazil's ANVISA and Chile's ISP? - Which key regulatory topics were discussed between July 6-10, 2026? - How could ANVISA's GMP certification process influence requirements in Chile? - What does this collaboration signal for the future of medical device regulation in Latin America? - How might import controls and post-market surveillance policies align between the two countries? - Why is regulatory convergence in LATAM important for medical device manufacturers? - What practical steps should regulatory teams take in response to this development? Sources: - https://www.pure-global.com/thought-leadership/anvisa-brazil-chile-regulatory-cooperation-2026/ How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies seeking to access markets in Latin America and over 30 countries worldwide. Our local experts in Brazil and other key markets offer on-the-ground support, from developing regulatory strategy and compiling technical dossiers to acting as your official in-country representative. We leverage advanced AI and data tools to streamline the submission process and monitor regulatory changes, ensuring your products achieve and maintain compliance efficiently. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn how we can accelerate your market entry. Explore our free AI tools and device database at https://pureglobal.ai.

ANVISA Technovigilance Changes in Brazil: What to Expect After the Public Consultation

This episode covers the recent closure of Brazil ANVISA's public consultation (Call for Contributions No. 4/2026) on a new technovigilance framework. We discuss the implications for medical device manufacturers, the expected changes to adverse event reporting and post-market surveillance, and practical steps to prepare for the upcoming regulations in Brazil. Key Questions: - What does the closing of ANVISA's public consultation on technovigilance mean for the industry? - How will the new framework likely change adverse event reporting in Brazil? - Who is responsible for complying with the upcoming technovigilance requirements? - What are the potential new timelines and definitions for reporting incidents? - How can manufacturers align their current processes with international standards in anticipation of the new rules? - What is the role of the Brazil Registration Holder (BRH) in this new framework? - What practical steps should regulatory and quality teams take right now? - When can we expect the final resolution from ANVISA to be published? Sources: - https://www.demarest.com.br/en/life-sciences-and-healthcare-newsletter-or-june-2026 How Pure Global can help: Pure Global provides comprehensive support for medical device manufacturers navigating complex regulatory landscapes like Brazil. Our experts can help you prepare for ANVISA's new technovigilance requirements, from developing a compliant post-market surveillance strategy to acting as your Brazil Registration Holder (BRH). We combine local expertise with advanced AI tools to streamline dossier preparation, manage submissions, and ensure your products remain compliant. To learn how we can accelerate your market access in Brazil and over 30 other countries, visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI regulatory tools and device database at https://pureglobal.ai.

South Korea Medical Device Act 2026: MFDS QMS and Distribution Rule Changes

This episode details the significant amendments to South Korea's Medical Device Act, effective July 1, 2026. We cover the two key changes from the Ministry of Food and Drug Safety (MFDS): the formalization of the Quality Management System (QMS) Conformity Recognition Scheme and the new mandatory supply chain record-keeping rules. We explore the impact on manufacturers, importers, and distributors and provide actionable steps for regulatory and quality teams to ensure compliance with these new traceability and oversight requirements. Key Questions: - What are the key changes in South Korea's amended Medical Device Act effective July 1, 2026? - How does the formalization of the QMS Conformity Recognition Scheme impact MFDS audits? - What new traceability and record-keeping requirements are being imposed on the medical device supply chain? - Who is responsible for maintaining distribution records under the new MFDS rules? - How does this amendment affect manufacturers, importers, distributors, and sellers in South Korea? - Can participation in programs like MDSAP simplify compliance with the new QMS requirements? - What practical steps should my regulatory team take now to prepare for the 2026 deadline? - How will these changes enhance patient safety and post-market surveillance in South Korea? Sources: - https://www.regdesk.co/south-korea-mfds-2026-medical-device-act-amendments-qms-conformity-recognition/ - https://www.youtube.com/watch?v=YOUR_VIDEO_ID_FOR_RESULT_16 How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, simplifying global market access. We act as your local representative in over 30 markets, including South Korea, and develop efficient regulatory strategies to get your products approved faster. Our AI-powered platform streamlines the creation and management of technical dossiers for MFDS submissions. We help you navigate complex requirements like the new distribution rules and ensure your QMS aligns with local expectations. Visit https://pureglobal.com or contact us at info@pureglobal.com. Explore our free AI tools and device database at https://pureglobal.ai.

Saudi Arabia SFDA Risk Communication Guidance: What MDS-G-029 Means for Manufacturers

The Saudi Food and Drug Authority (SFDA) published a new guidance, MDS-G-029, on July 9, 2026, establishing formal requirements for medical device risk communication. This episode breaks down the key principles of the guidance, including the responsibilities of manufacturers and their Authorized Representatives, the expected content and channels for communication, and the impact on post-market surveillance and vigilance systems for devices sold in Saudi Arabia. Key Questions: - What is the new SFDA guidance MDS-G-029 about? - Who does this new risk communication requirement apply to? - What are the key principles for communicating medical device risks in Saudi Arabia? - What specific information must be included in a risk communication notice? - How does this guidance impact manufacturers' post-market surveillance obligations? - What is the role of the Authorized Representative in this process? - What are the different types of communication channels the SFDA expects? - What practical steps should my team take now to prepare for compliance? Sources: - https://www.sfda.gov.sa/sites/default/files/2026-07/MDS-G-029-V1.pdf - https://www.sfda.gov.sa/en/medicaldevices How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, including Saudi Arabia, and our experts can help you align your post-market surveillance and vigilance systems with new requirements like the SFDA's MDS-G-029. Our AI-powered tools accelerate the creation of technical documentation and help you monitor regulatory changes, ensuring continuous compliance. Whether you need to develop a regulatory strategy, manage submissions, or maintain your market presence, we offer a single, efficient process for multiple markets. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn more and access our free regulatory AI tools and database at https://pureglobal.ai.

Health Canada Ministerial Reliance Order: Faster Market Access for Medical Devices

Health Canada has introduced a new Ministerial Reliance Order, effective July 15, 2026, designed to accelerate market access for medical devices and drugs. This episode breaks down how the new reliance pathway allows manufacturers to leverage approvals from trusted foreign regulators to expedite the Canadian review process. We discuss the potential eligibility criteria, the critical public consultation period ending on September 12, 2026, and provide practical, actionable steps for regulatory and quality teams to prepare their submission strategies. Key Questions: - What is Health Canada's new Ministerial Reliance Order? - How does this order accelerate the review process for medical devices? - Which foreign regulatory approvals will Health Canada likely recognize? - What are the potential eligibility criteria for devices under this new pathway? - Why is the September 12, 2026, deadline for public consultation so important? - How can manufacturers prepare their submissions to leverage this reliance route? - What documentation is needed to demonstrate equivalence with a foreign approval? - What are the immediate implications of this order for your Canadian market access strategy? - Should you re-prioritize Canada in your global launch sequence? Sources: - https://www.canada.ca/en/health-canada/news/2026/07/helping-canadians-access-safe-effective-treatments-and-medicines-faster.html How Pure Global can help: Navigating new regulatory pathways like Health Canada's Ministerial Reliance Order requires local expertise and a clear strategy. Pure Global provides end-to-end support for MedTech and IVD companies, acting as your local representative and developing efficient pathways for regulatory approval in Canada and over 30 other markets. Our experts use advanced AI to compile and manage technical dossiers, ensuring your submissions are optimized for accelerated review. Let us help you leverage your existing approvals to access the Canadian market faster. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.